m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05234
 [1]
Non-coding RNA miR-141-3p ALKBH5  lncRNA       miRNA   circRNA Direct Inhibition m6A modification MMP9 MMP9 ALKBH5 Demethylation : m6A sites
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
m6A Target Matrix metalloproteinase-9 (MMP9)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-141-3p microRNA View Details
Regulated Target RNA demethylase ALKBH5 (ALKBH5) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary Silencing MALAT1 led to down-regulation of the N6-methyladenosine (m6A) demethylase ALKBH5 via regulating hsa-miR-141-3p expression, which caused a decrease in the expression levels of MMP2 and Matrix metalloproteinase-9 (MMP9) expression, thereby suppressing cell migration and invasion.
Responsed Disease Cervical cancer ICD-11: 2C77
 Disease Info 
In-vitro Model
 C-33 A Cervical squamous cell carcinoma Homo sapiens CVCL_1094
HeLa Endocervical adenocarcinoma Homo sapiens CVCL_0030
Ca Ski Cervical squamous cell carcinoma Homo sapiens CVCL_1100
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Matrix metalloproteinase-9 (MMP9) 56 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name DP-b99 Phase 3 [2]
Synonyms
343340-21-6; 222315-88-0; SCHEMBL720046; DP-b 99; DTXSID20187908; DP-BAPTA-99, DP-b99; ZINC162948634; 2,2'-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis((2-(2-(octyloxy)ethoxy)-2-oxoethyl)azanediyl))diacetic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9810955
TTD: D04PWT
 Compound Name GS-5745 Phase 3 [3]
MOA Modulator
External Link
CID: 56776542
TTD: D0WL0Q
 Compound Name Andecaliximab Phase 3 [4]
External Link
TTD: D0Z6SP
 Compound Name Curcumin Phase 3 [5]
Synonyms
458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 969516
TTD: D07SDQ
DrugBank: DB11672
 Compound Name BLZ-100 Phase 1/2 [6]
Synonyms
Tozuleristide; UNII-835UH424TU; 835UH424TU; Tozuleristide [INN]; Tozuleristide [USAN]; 1673565-40-6
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 121488172
TTD: D0I8KA
 Compound Name Neovastat Phase 1 [7]
MOA Inhibitor
External Link
TTD: D0T4BL
 Compound Name PMID29130358-Compound-Figure17(13) Patented [8]
MOA Inhibitor
Activity IC50 < 10000 nM; IC50 > 10 nM
External Link
TTD: D0LP0D
 Compound Name PMID29130358-Compound-Figure17(12) Patented [8]
MOA Inhibitor
Activity IC50 < 10000 nM
External Link
TTD: D00ZZJ
 Compound Name PMID29130358-Compound-Figure17(10) Patented [8]
MOA Inhibitor
Activity IC50 > 1000 nM; IC50 < 10000 nM
External Link
TTD: D09ATD
 Compound Name PMID29130358-Compound-SB-3CT Patented [8]
MOA Inhibitor
Activity IC50 = 600 nM
External Link
TTD: D0DB0Z
 Compound Name PMID29130358-Compound-Figure17(11) Patented [8]
MOA Inhibitor
Activity IC50 > 130 nM; IC50 < 10000 nM
External Link
TTD: D0L6HL
 Compound Name PMID29130358-Compound-Figure13(4) Patented [8]
MOA Inhibitor
External Link
TTD: D0Q4QB
 Compound Name PMID29130358-Compound-LonimacranthoideVII Patented [8]
MOA Inhibitor
External Link
TTD: D0W7HO
 Compound Name PMID29130358-Compound-Figure18(14a) Patented [8]
MOA Inhibitor
Activity IC50 = 2500 nM
External Link
TTD: D0X6GG
 Compound Name Galarubicin Discontinued in Phase 2 [9]
Synonyms
DA-125; Metalloprotease inhibitors (cancer), Dong-A
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 114759
TTD: D05WTZ
 Compound Name RS-130830 Discontinued in Phase 2 [10]
Synonyms
CTS-1027; 193022-04-7; UNII-2QD3F58224; CHEMBL440498; 2QD3F58224; 4-[4-(4-CHLORO-PHENOXY)-BENZENESULFONYLMETHYL]-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HYDROXYAMIDE; 4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide; 4-(4-(4-Chloro-phenoxy)-benzenesulfonylmethyl)-tetrahydro-pyran-4-carboxylic acid hydroxyamide; Ro-1130830; AC1MOE9A; SCHEMBL2381112; BDBM11863; DTXSID90172907; 830c; CTS 1027; ZINC1488366; BCP13018; 3563AH; alpha-tetrahydropyran beta-sulfone 1B; AKOS030526690
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.11 nM
External Link
CID: 3342298
TTD: D03BOZ
DrugBank: DB08490
 Compound Name GM6001 Discontinued in Phase 2 [11]
Synonyms
Ilomastat; Galardin; 142880-36-2; GM 6001; Illomastat; CS 610; GM-6001; UNII-I0403ML141; CHEMBL19611; Ilomastat (GM6001, Galardin); I0403ML141; NCGC00163450-02; 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE; (R)-N4-Hydroxy-N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobutyl-succinamide; N-[(2R)-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide; (R)-N(sup 1)-Hydroxy-N-((S)-2-indol-3-yl-1-(methylcarbamoyl)ethyl)-2-isobutylsuccinamide; (S-(R*,S*))-N(sup 4)-Hydroxy-N(sup
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.05 nM
External Link
CID: 132519
TTD: D0T9HG
DrugBank: DB02255
 Compound Name DX-2802 Preclinical [12]
External Link
TTD: D05VEP
 Compound Name CT-1746 Terminated [13]
MOA Modulator
External Link
CID: 9930721
TTD: D0O7DU
 Compound Name CDP-845 Terminated [14]
MOA Modulator
External Link
TTD: D02GYD
 Compound Name RO-319790 Terminated [15]
Synonyms
Ro-31-9790; CHEMBL16520; Ro 31-9790; (R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide; SCHEMBL4633699; QRXOZHSEEGNRFC-ZYHUDNBSSA-N; ZINC1534591; BDBM50063920; CS-6682; HY-101703
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 2 nM
External Link
CID: 9904965
TTD: D0E5GY
 Compound Name SC-44463 Terminated [16]
Synonyms
CHEMBL45483; n-[3-(n'-hydroxycarboxamido)-2-(2-methylpropyl)-propanoyl]-o-tyrosine-n-methylamide; 104408-38-0; Ihp-tyr-menh2; HTA; AC1L2U0O; SCHEMBL9284838; sc44463; BDBM50104969; DB07926; N-(2-Isobutyl-3-(N'-hydroxycarbonylamido)propanoyl)-O-methyltyrosinemethylamide; N*4*-Hydroxy-2-isobutyl-N*1*-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethyl]-succinamide; (2R)-N-hydroxy-N'-[(1S)-2-(4-methoxyphenyl)-1-(methylcarbamoyl)ethyl]-2-(2-methylpropyl)butanediamide; Butanediamide, N4-hydroxy-N1-(1-((4-methoxyphenyl)meth
    Click to Show/Hide
MOA Inhibitor
Activity Ki < 1 nM
External Link
CID: 128564
TTD: D0Y1XT
DrugBank: DB07926
 Compound Name 2-Amino-N,3,3-Trimethylbutanamide Investigative [17]
Synonyms
AC1MRP6C; SCHEMBL343358; DTXSID30393038; BPKJNEIOHOEWLO-UHFFFAOYSA-N; 2-amino-N,3,3-trimethyl-butanamide; 2-azanyl-N,3,3-trimethyl-butanamide; AKOS022475747; AN-25241
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3496445
TTD: D00CWH
 Compound Name PMID15055993C1a Investigative [18]
Synonyms
GTPL6514; BDBM50131385
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.06 nM
External Link
CID: 9910222
TTD: D03WJG
 Compound Name Carboxylated glucosamine Investigative [19]
MOA Inhibitor
External Link
CID: 44411803
TTD: D03ZDZ
 Compound Name Methotrexate gamma-L-phenylalaninehydroxamic acid Investigative [20]
Synonyms
CHEMBL396296
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 15000 nM
External Link
CID: 16216218
TTD: D04PAW
 Compound Name 5-Methyl-5-phenyl-pyrimidine-2,4,6-trione Investigative [21]
Synonyms
Heptobarbital; Mephebarbital; Eudan; Phenylmethylbarbituric acid; Rutonal; Methylphenylbarbital; 5-Methyl-5-phenylbarbituric acid; 5-Methyl-5-phenylbarbityric acid; 76-94-8; 5-Phenyl-5-methylbarbituric acid; NSC 80543; Barbituric acid, 5-methyl-5-phenyl-; UNII-GFR227X6YY; 5-Methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; EINECS 200-994-8; BRN 0201825; GFR227X6YY; CHEMBL329617; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-methyl-5-phenyl-; 5-methyl-5-phenyl-barbituric acid; C11H10N2O3; 5-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 11000 nM
External Link
CID: 66160
TTD: D09GIL
 Compound Name ARP100 Investigative [22]
Synonyms
ARP 100; ARP-100
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 200 nM
External Link
CID: 10044321
TTD: D0Q4TA
 Compound Name Ro 28-2653 Investigative [23]
Synonyms
Ro-28-2653; 261956-22-3; CHEMBL456911; SCHEMBL726759; SCHEMBL8471189; EX-A2614; BDBM50363130; ZINC33975062; Ro28-2653; KB-275261; 5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7 nM
External Link
CID: 9832179
TTD: D0Z4LO
 Compound Name Methotrexate gamma-L-proline-hydroxamic acid Investigative [20]
Synonyms
CHEMBL388879
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44428667
TTD: D01HKU
 Compound Name PMID23631440C29e Investigative [24]
Synonyms
GTPL8578; BDBM50433865
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1.5 nM
External Link
CID: 46175162
TTD: D07DRT
 Compound Name 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione Investigative [21]
Synonyms
CHEMBL176517; 219311-20-3; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(4-phenoxyphenyl)-; SCHEMBL6380971; CTK0J6997; DTXSID60470422; NNRYJLARUIVRRO-UHFFFAOYSA-N; 5-(4'-phenoxyphenyl)barbituric acid; 5-(4-phenoxyphenyl)pyrimidine-2,4,6-trione
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 53742316
TTD: D07LTB
 Compound Name Methotrexate gamma-hydroxamic acid Investigative [20]
Synonyms
CHEMBL244883
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44428664
TTD: D0B0UI
 Compound Name 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid Investigative [25]
Synonyms
CHEMBL378740; BDBM50185874; 2-(4''-chloro-biphenyl-4-sulfonyl)-pentanoic acid
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10005 nM
External Link
CID: 44411812
TTD: D0E5MB
 Compound Name 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione Investigative [21]
Synonyms
5-Hexyl-5-phenylbarbituric acid; BRN 0297956; BARBITURIC ACID, 5-HEXYL-5-PHENYL-; 67051-21-2; CHEMBL173075; AC1L2LKK; 4-24-00-02103 (Beilstein Handbook Reference); CTK8J9653; DTXSID20217355; 5-hexyl-5-phenyl barbituric acid; BDBM50099125; LS-24512
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 330 nM
External Link
CID: 49292
TTD: D0K4TI
 Compound Name 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione Investigative [21]
Synonyms
CHEMBL175282; BDBM50099116
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 863 nM
External Link
CID: 44385624
TTD: D0Q9LC
 Compound Name Roche 28-2653 Investigative [23]
MOA Inhibitor
External Link
CID: 56603788
TTD: D0U7CD
 Compound Name N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide Investigative [26]
Synonyms
CHEMBL252674; 2H-1-Benzopyran-3-propanamide, N-hydroxy-2-oxo-; BDBM50224963
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1410 nM
External Link
CID: 44446270
TTD: D00RNA
 Compound Name 2-(biphenyl-4-ylsulfonamido)pentanedioic acid Investigative [27]
Synonyms
CHEMBL475540; 2-(Biphenyl-4-sulfonylamino)-pentanedioic acid; SR-01000365325; BAS 07869980; AC1LD9LY; MLS000075919; CHEBI:91838; HMS2373B21; ML034; BDBM50247207; AKOS000737926; AKOS024284065; MCULE-3770968562; ST072428; SMR000014780; 2-[(4-phenylphenyl)sulfonylamino]pentanedioic acid; SR-01000365325-1; SR-01000365325-3; 2-{[(4-phenylphenyl)sulfonyl]amino}pentanedioic acid
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 14000 nM
External Link
CID: 644601
TTD: D03SNK
 Compound Name N-hydroxy-2,3-bis(phenylsulfonamido)propanamide Investigative [28]
Synonyms
CHEMBL496717
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 227 nM
External Link
CID: 24857837
TTD: D07SPC
 Compound Name N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) Investigative [26]
Synonyms
CHEMBL402990
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5660 nM
External Link
CID: 44446277
TTD: D08ICI
 Compound Name 3-(4-Phenylethynylbenzoyl)nonanoic acid Investigative [29]
Synonyms
CHEMBL201298
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5410 nM
External Link
CID: 11581319
TTD: D0A5MV
 Compound Name Folate gamma-hydroxamic acid Investigative [20]
MOA Inhibitor
External Link
CID: 136177317
TTD: D0P8EY
 Compound Name 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid Investigative [27]
Synonyms
CHEMBL448246; 3-(4-Hexyloxy-phenyl)-succinamic acid; AC1LCKXS; SMR000008837; MLS000073581; cid_651854; HMS2162F22; HMS3313H20; BDBM50247490; AKOS000505159; AKOS030483668; BAS 00404306; 4-amino-3-(4-hexoxyphenyl)-4-oxobutanoic acid; SR-01000514729
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 160 nM
External Link
CID: 651854
TTD: D0V9GS
 Compound Name 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione Investigative [21]
Synonyms
CHEMBL367524; 94209-48-0; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-[1,1'-biphenyl]-4-yl-5-ethyl-; ACMC-20lyhc; AC1M3WRE; Oprea1_691960; MLS001000776; NIOSH/CQ0532020; CTK3G9325; DTXSID20367041; MolPort-002-095-507; HMS2827O03; BDBM50099119; ZINC96299878; STK760260; AKOS005616072; MCULE-2406616532; Acido 5-etil 5-(p-difenilil)barbiturici; NCGC00245692-01; 5-(4-Biphenylyl)-5-ethylbarbituric acid; SMR000498104; LS-23825; M.G. 3419; CQ05320200; Barbituric acid, 5-(4-biphenylyl)-5-ethyl-
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 696 nM
External Link
CID: 2220392
TTD: D0Y7NV
 Compound Name (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid Investigative [30]
Synonyms
CHEMBL572982; SCHEMBL5613354; ILGSIIFHQGOKKV-UHFFFAOYSA-N; BDBM50300465; 5-biphenyl-4-yl-3-hydroxy-pentanoic acid; 5-(biphenyl-4-yl)-3-hydroxypentanoic acid
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 16500 nM
External Link
CID: 11391583
TTD: D0G3YZ
 Compound Name 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid Investigative [29]
Synonyms
CHEMBL202875
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3600 nM
External Link
CID: 11609208
TTD: D0L4EO
 Compound Name UK-356618 Investigative [31]
Synonyms
UK 356618; 230961-08-7; CHEMBL117225; UK-356,618; SCHEMBL6437730; GTPL6528; CHEBI:94305; DTXSID50438778; MolPort-023-277-089; ZINC3924338; BDBM50097263; AKOS024458021; FT-0675728; PF 03890101; PF-03890101; UK-356618, &gt; J-014983; BRD-K57011718-001-01-5; (R)-N*1*-[(S)-2,2-Dimethyl-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-N*4*-hydroxy-2-[3-(2-methyl-biphenyl-4-yl)-propyl]-succinamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 840 nM
External Link
CID: 10370504
TTD: D0NP8A
 Compound Name Ro-37-9790 Investigative [32]
Synonyms
CHEMBL306412; BDBM50290086
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10.4 nM
External Link
CID: 44313734
TTD: D0XL8K
 Compound Name 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide Investigative [33]
Synonyms
CHEMBL574589
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7700 nM
External Link
CID: 44478925
TTD: D05THD
 Compound Name SL422 Investigative [34]
Synonyms
analogue 55f [PMID: 11472217]
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.9 nM
External Link
CID: 10344307
TTD: D07GEL
 Compound Name [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid Investigative [33]
Synonyms
CHEMBL573935
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7300 nM
External Link
CID: 44479701
TTD: D07MJD
 Compound Name N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide Investigative [33]
Synonyms
CHEMBL575896
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 690 nM
External Link
CID: 10155934
TTD: D0S9OL
 Compound Name SR-973 Investigative [35]
Synonyms
CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 5 nM
External Link
CID: 9849669
TTD: D03AMR
 Compound Name IK-862 Investigative [36]
Synonyms
YDMIPBHQKFOFQW-NSYGIPOTSA-N; (2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE; CHEMBL148169; CHEBI:40083; (2R)-N-hydroxy-2-[(3S)-3-methyl-3-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]-2-oxopyrrolidin-1-yl]propanamide; IK862; 2fv5; AC1OCAC0; BMCL181958 Compound 1; GTPL8680; SCHEMBL5966106; BDBM26526; IK682; DB07145; C468787000; (R)-2-[(3S)-2-Oxo-3alpha-[4-(2-methyl-4-quinolinylmethoxy)phenyl]-3-methylpyrrolizino]propanehydroximic; IK 862; compound 32; IK-682
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 10340 nM
External Link
CID: 6914621
TTD: D0W2UK
DrugBank: DB07145
 Compound Name MMI270 Investigative [37]
Synonyms
CGS-27023A; CGS-27023; UNII-80AXY59IT2; 80AXY59IT2; N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE; CHEMBL514138; (2R)-N-hydroxy-2-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-3-methylbutanamide; CGS; 1eub; MMI270B free base; hydroxamate analogue 1; 2w0d; 1bm6; MMI-270B free base; AC1L9JQY; 3MP-HAV-MSB; CGS-27023A free base; BMCL16311 Compound 1a; BDBM8465; SCHEMBL3468445; GTPL8846; CHEMBL267178; BSIZUMJRKYHEBR-QGZVFWFLSA-N; CGS 27023; BDBM50066658; DB07556; 161314-70-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4.3 nM
External Link
CID: 446504
TTD: D0A4TC
DrugBank: DB07556
References
Ref 1 The involvement of MALAT1-ALKBH5 signaling axis into proliferation and metastasis of human papillomavirus-positive cervical cancer. Cancer Biol Ther. 2023 Dec 31;24(1):2249174. doi: 10.1080/15384047.2023.2249174.
Ref 2 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789. doi: 10.1371/journal.pone.0099789. eCollection 2014.
Ref 3 National Cancer Institute Drug Dictionary (drug id 747683).
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. Bioorg Med Chem. 2009 Feb 1;17(3):1290-6. doi: 10.1016/j.bmc.2008.12.029. Epub 2009 Jan 6.
Ref 6 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. doi: 10.1038/s41573-019-0013-8.
Ref 7 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. doi: 10.1016/s0093-7754(01)90035-1.
Ref 8 Gelatinase inhibitors: a patent review (2011-2017). Expert Opin Ther Pat. 2018 Jan;28(1):31-46. doi: 10.1080/13543776.2018.1397132. Epub 2017 Nov 12.
Ref 9 Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix metalloproteinases. Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31. doi: 10.1016/j.bcp.2005.10.007. Epub 2005 Nov 2.
Ref 10 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6. doi: 10.1016/j.bmcl.2004.12.016.
Ref 11 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity. Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. doi: 10.1016/j.bmc.2008.07.041. Epub 2008 Jul 20.
Ref 12 Clinical pipeline report, company report or official report of DeepDyve.
Ref 13 Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis. 1997 Mar;15(2):184-95. doi: 10.1023/a:1018461112732.
Ref 14 Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29. doi: 10.2165/00126839-199901020-00001.
Ref 15 The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8. doi: 10.1016/s0960-894x(98)00186-3.
Ref 16 Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. J Med Chem. 2001 Oct 11;44(21):3347-50. doi: 10.1021/jm015533c.
Ref 17 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 18 Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem. 2004 Apr 8;47(8):1930-8. doi: 10.1021/jm0304313.
Ref 19 Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3105-10. doi: 10.1016/j.bmcl.2006.03.077. Epub 2006 Apr 17.
Ref 20 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. doi: 10.1016/j.bmc.2006.11.017. Epub 2006 Nov 14.
Ref 21 Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. doi: 10.1016/s0960-894x(01)00104-4.
Ref 22 Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg Med Chem. 2006 Jun 15;14(12):4260-76. doi: 10.1016/j.bmc.2006.01.056. Epub 2006 Feb 17.
Ref 23 The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96. doi: 10.1038/sj.onc.1205267.
Ref 24 Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73.
Ref 25 Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100. doi: 10.1016/j.bmcl.2006.03.065. Epub 2006 May 2.
Ref 26 Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. doi: 10.1016/j.bmc.2007.09.014. Epub 2007 Sep 14.
Ref 27 Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. doi: 10.1016/j.bmc.2008.03.018. Epub 2008 Mar 8.
Ref 28 Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7. doi: 10.1016/j.bmcl.2008.04.035. Epub 2008 Apr 16.
Ref 29 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. doi: 10.1021/jm051101g.
Ref 30 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. doi: 10.1016/j.bmcl.2009.07.155. Epub 2009 Aug 6.
Ref 31 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. doi: 10.1021/jm0308038.
Ref 32 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
Ref 33 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. J Med Chem. 2009 Oct 22;52(20):6347-61. doi: 10.1021/jm900335a.
Ref 34 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. doi: 10.1021/jm010127e.
Ref 35 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. doi: 10.1016/j.bmcl.2006.01.055. Epub 2006 Feb 10.
Ref 36 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. J Med Chem. 2002 Nov 7;45(23):4954-7. doi: 10.1021/jm0255670.
Ref 37 Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6. doi: 10.1016/s0960-894x(99)00259-0.